Elanco Animal Health Incorporated

- There is no mention of any new fundraising through debt or equity in the current or future plans. - The company is focused on paying down existing debt, aiming to reduce net leverage below 3x by 2027. - Debt paydown remains the primary use of free cash flow. - Capital allocation priorities include organic investment, debt reduction, and small tuck-in M&A. - The company expects greater capital allocation flexibility once leverage is below 3x, potentially enabling shareholder returns. - No explicit plans for raising new capital via equity or debt were disclosed. - The firm is maintaining a balanced and prudent financial approach amid potential external headwinds.

- No specific mention of current or future capital expenditures (capex) or strategic investments detailed explicitly in the provided pages. - Capital allocation priorities focus primarily on organic growth investments and debt reduction. - Small tuck-in M&A opportunities will continue but remain disciplined so as not to derail deleveraging progress. - No indication of large M&A deals planned at this time despite hitting leverage targets earlier. - Flexibility for more capital deployment and shareholder returns anticipated when net leverage falls below 3x around 2027. - Continued investments expected in innovation product launches, marketing (including DTC), and R&D to fuel growth. - Elanco Ascend initiative targets operational efficiencies and margin expansion, with savings mostly impacting gross margin and G&A costs. - Mention of closing AHV International acquisition (farm animal sector) on April 30 as a recent strategic move expanding dairy presence.

- Elanco expects continued momentum with high single-digit to low double-digit growth in U.S. Pet Health in H2 2026, driven by innovation launches like Zenrelia, Credelio Quattro, and Befrena. - The full year 2026 U.S. Pet Health business is forecasted to deliver at least high single-digit revenue growth. - Farm Animal segment shows durable trends with continued growth; poultry growing 3% annually, dairy gaining momentum, and cattle herd rebuild supporting volume increases. - International derm market (e.g., Zenrelia) is growing double digits, faster than U.S., with expansion into 44 countries and more share gains expected. - Global innovation pipeline targets 5-6 new blockbusters by 2031, unlocking over $2 billion in peak sales potential. - Overall company revenue guidance raised to 5-7% organic constant currency growth in 2026. - Pricing is expected to accelerate in 2026 due to innovation and value-based pricing strategies. - Growth supported by omnichannel reach, corporate account expansion, and operational efficiencies via Elanco Ascend.

- Full-year 2026 organic constant currency revenue growth is expected at 5% to 7%, up from a prior outlook of 4% to 6%. - Adjusted EBITDA guidance for 2026 is raised by $20 million to a range of $975 million to $1.005 billion, representing about 10% growth at midpoint. - Adjusted EPS guidance is increased by $0.03 to a range of $1.03 to $1.09, reflecting 13% growth at midpoint. - Q2 2026 revenue forecast is $1.3 billion to $1.325 billion with organic constant currency growth of 4% to 6%. - Operating expenses expected to increase about 8% in constant currency due to launch investments. - U.S. Pet Health business anticipated to accelerate to high single-digit to low double-digit growth in the second half of 2026. - Innovation products ("Big 6") expected to double revenue from 2025 to 2028. - Margin expansion targeted via operational efficiencies and improved product mix starting in 2026.

The transcript does not provide specific figures or detailed information regarding current or expected orderbook or pending orders. However, relevant insights from the call include: - Strong momentum in new product launches (Zenrelia, Quattro, Befrena) contributing to growth and order intake. - Corporate accounts showing a 12% step-up with increasing commitments, indicating a growing order pipeline. - Retail partnerships (Costco, Dollar General) expected to ramp through 2026 and beyond, contributing seasonal orders primarily in the first half of the year. - Ongoing reinvestments in marketing and direct-to-consumer initiatives supporting order growth. - Confidence expressed for second half of 2026 due to strong order rates and continued corporate account ramps. - The company remains cautious but optimistic about order trends despite macro uncertainties.